Answers are grounded in this paper and cite their sources.
Clinical review evaluates the therapeutic role and controversies of PARP inhibitors in metastatic castration-resistant prostate cancer, highlighting ongoing challenges in patient selection.
The clinical utility of PARP inhibitors (PARPi) has been established in metastatic castration-resistant prostate cancer (mCRPC), now referred to as metastatic androgen pathway modulation–resista...
No takes yet. Share an insight, caveat, or question.
Azad et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: